Iovance Biotherapeutics, Inc.

NASDAQ:IOVA

Biotechnology

Healthcare
$7.48 -0.89%

-$0.04 today

Market cap
$3.46B
Beta
0.70
P/E (TTM)
-4.6
EPS (TTM)
-$0.85
52W Low $1.66High $5.63

Volume 6.99M

Average 14.09M

Income Statement

Follow revenue through to earnings.

Revenue

$263.50M

FY 2025 · Annual

+60.6% YoY

Operating Income

-$398.21M

FY 2025 · Annual

Net Income

-$390.98M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue001.19M164.07M263.5M
Cost of Revenue0010.76M124M173.18M
Gross Profit00(9.57M)40.08M90.32M
Gross Margin——-804.5%24.4%34.3%
Research & Development259.04M294.78M344.08M282.34M300.27M
Selling, General & Admin83.66M104.1M106.92M153.02M152.32M
Operating Expenses342.7M398.88M450.99M435.35M488.53M
Depreciation & Amortization13.98M21.14M33.13M43.61M47.32M
EBITDA(328.27M)(371.77M)(414.39M)(331.4M)(350.89M)
EBITDA Margin——-34851.9%-202.0%-133.2%
Operating Income(342.7M)(398.88M)(460.56M)(395.28M)(398.21M)
Operating Margin——-38735.0%-240.9%-151.1%
Interest Income451K2.99M13.04M20.27M10.31M
Interest Expense02.99M000
Other Income / Expenses451K2.99M13.04M20.27M5.16M
Income Before Tax(342.25M)(395.89M)(447.52M)(375.01M)(393.05M)
Pre-Tax Margin——-37638.0%-228.6%-149.2%
Income Tax Expense00(3.48M)(2.83M)(2.07M)
Net Income(342.25M)(395.89M)(444.04M)(372.18M)(390.98M)
Net Margin——-37345.4%-226.8%-148.4%
EPS (Basic)(2.23)(2.49)(1.89)(1.28)(1.09)
EPS (Diluted)(2.23)(2.49)(1.89)(1.28)(1.09)
Weighted Avg Shares153.41M159.26M235.13M289.88M357.35M
Weighted Avg Shares (Diluted)153.41M159.26M235.13M289.88M357.35M

IOVA Earnings Waterfall · TTM

NASDAQ:IOVA · Revenue to Net Income

Key Ratios

EPS$-0.53
Gross Margin51.8%
Net Margin-64.9%
P/E Ratio-23.0
P/S Ratio27.0

Analysis

$379.0M of revenue converted into -$220.5M of net income for the selected period. Gross margin is 51.8% and net margin is -64.9%, showing how much revenue survives after costs and taxes. EPS is $-0.53, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 13, 2026
4Statement of changes in beneficial ownershipNov 12, 2026
SC 13GSC 13G filingNov 10, 2026
4Statement of changes in beneficial ownershipNov 10, 2026
10-QQuarterly reportNov 5, 2026

How much revenue does IOVA generate?

Iovance Biotherapeutics, Inc. (IOVA) reported $263.50M of revenue in fiscal 2025.

Is IOVA profitable?

Iovance Biotherapeutics, Inc. (IOVA) reported -$390.98M of net income, with a net margin of -148.4%.